<b>Conclusions</b>: TPGs ameliorate RA by targeting the succinate-GPR91-Th17 pathway, identifying succinate as a novel RA target and TPGs as a potential microbiota-modulating agent. This evidence concerns the gene SUCNR1 and rheumatoid arthritis.